Get started
Author

Concetta Sergi

Observed names: C. Sergi, Sergi, Concetta
Institution: Ospedale Garibaldi
ORCID: 0000-0003-0814-3148
Observed ORCID: 0000-0003-0814-3148
OpenAlex ID: A5091893637
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial
2023 · Sandro Pignata, Giovanni Scambia, et al. · The Lancet Oncology · 57
Virtual Multidisciplinary Tumor Boards: A Narrative Review Focused on Lung Cancer
2021 · Vittorio Gebbia, Aurelia Guarini, et al. · Pulmonary Therapy · 45
PDF
Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma
2004 · Vincenzo Adamo, Giuseppa Ferraro, et al. · Oral Oncology · 43
Consolidative thoracic radiation therapy for extensive-stage small cell lung cancer in the era of first-line chemoimmunotherapy: preclinical data and a retrospective study in Southern Italy
2024 · Vito Longo, Carminia Maria Della Corte, et al. · Frontiers in Immunology · 27
Detection of ALK fusion variants by RNA-based NGS and clinical outcome correlation in NSCLC patients treated with ALK-TKI sequences
2022 · Fabrizio Tabbò, Lucia Anna Muscarella, et al. · European Journal of Cancer · 16
Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients
2019 · Maria Lucia Reale, Rita Chiari, et al. · Lung Cancer · 14
Out-of-pocket costs in gastrointestinal cancer patients: Lack of a perfectly framed problem contributing to financial toxicity
2021 · Roberto Bordonaro, Dario Piazza, et al. · Critical Reviews in Oncology/Hematology · 10
Induction Chemotherapy to Weekly Paclitaxel Concurrent with Curative Radiotherapy in Stage IV (M0) Unresectable Head and Neck Squamous Cell Carcinoma: a Dose Escalation Study
2004 · S. Pergolizzi, V. Adamo, et al. · Journal of Chemotherapy · 6
Advanced-stage ALK-positive non–small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database
2025 · Maria Lucia Reale, Daniela Scattolin, et al. · Lung Cancer · 5
PDF
Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study
2019 · E. Gobbini, R. Chiari, et al. · Clinical & Translational Oncology · 5
EGFR-mutant NSCLC progressing on first-line osimertinib: rebiopsy in real-world and impact of second-line therapies (the “Rebiopsy on Osi” study)
2026 · Eleonora Gariazzo, Francesca Colamartini, et al. · The Oncologist · 1
PDF
Amivantamab in advanced non–small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: Real‐world data from the Italian ATLAS Registry
2026 · Francesco Passiglia, Antonio Passaro, et al. · Cancer · 1
PDF
Adjuvant atezolizumab in surgically resected NSCLC patients with PD-L1 expression ≥ 50%: real-world data from the Italian ATLAS registry
2025 · Francesco Passiglia, Maria Lucia Reale, et al. · The Oncologist · 1
MA26.02 Upfront or Sequential Strategy for New Generation Anaplastic Lymphoma Kinase (ALK) Inhibitors: An Italian Retrospective Study.
2018 · E. Gobbini, P. Pizzutilo, et al. · Journal of Thoracic Oncology · 1
Activity and safety of CPBev regimen (cisplatinum, pemetrexed, and bevacizumab) as first-line therapy for locally advanced or metastatic adenocarcinoma of the lung: Final results of a phase II study.
2012 · Roberto Bordonaro, Hector Soto-parra, et al. · Journal of Clinical Oncology · 1
MAP of molecular analyses in real-worlD oncology centers – MAPpaMoNDO: a study of the translational research Young GOIM group
2026 · Federica Papaccio, Pasquale Lombardi, et al. · Journal of Translational Medicine
Corrigendum to ’Real-life management of stage III non-small cell lung cancer patients in Italy: the BE-PACIFIC observational study’ [Cancer Treat Res Commun. 2026:47:101143]
2026 · Paolo Bironzo, Alessandro Morabito, et al. · Cancer Treatment and Research Communications
PDF
Real-life management of stage III non-small cell lung cancer patients in Italy: the BE-PACIFIC observational study
2026 · Paolo Bironzo, Alessandro Morabito, et al. · Cancer Treatment and Research Communications
PDF
Braf-mutant metastatic non–small-cell lung cancer: Real world data from the Italian biomarker atlas database
2025 · Claudio Sini, Alessandro Russo, et al. · European Journal of Cancer
P1.07.51 Safety and Tolerability of Adjuvant Atezolizumab in Pd-L1>50% NSCLC Patients: Real-World Data From the Italian ATLAS Registry
2025 · M.L. Reale, F. Passiglia, et al. · Journal of Thoracic Oncology
P3.12.15 Activity and Tolerability of MET Tkis in METex14 NSCLC: Updated Real-World Data From the Italian Biomarker Atlas Database
2025 · M.L. Reale, A. Mogavero, et al. · Journal of Thoracic Oncology
P3.18.18 Predictive Role of Respiratory Function Tests on Lung Toxicity in Stage III NSCLC Under Chemo-Radiotherapy and Durvalumab: Preludio Trial
2025 · P.M. Medusa, C.M. Della Corte, et al. · Journal of Thoracic Oncology
Predictive role of functional respiratory tests in LUng toxicity in stage III NSCLC treated with chemo-, raDIO- and immuno-therapy: PRELUDIO TRIAL
2025 · P.M. Medusa, N. Carro, et al. · Lung Cancer
EP05.01-024 Real-life Management of Stage III NSCLC Patients in Italy: The BE-PACIFIC Observational Study
2022 · S. Novello, A. Morabito, et al. · Journal of Thoracic Oncology
EP06.01-006 Multidisciplinary Team during the COVID-19 Pandemic: The BE-PACIFIC Italian Observational Study Analysis
2022 · S. Ramella, A. Morabito, et al. · Journal of Thoracic Oncology
Works count: 31
Citation count: 233
H-index: 7
I10-index: 7
Year
Topic
Type